Compounds > db 766
Page last updated: 2024-10-15

db 766

Cross-References

ID SourceID
PubMed CID135530739
CHEMBL ID1275764
MeSH IDM0549803

Synonyms (8)

Synonym
CHEMBL1275764
db-766
423165-22-4
2-pyridinecarboximidamide, n,n''-(2,5-furandiylbis(3-(1-methylethoxy)-4,1-phenylene))bis-
59dsb6bo43 ,
unii-59dsb6bo43
n-[3-isopropoxy-4-[5-[2-isopropoxy-4-(pyridine-2-carboximidoylamino)phenyl]-2-furyl]phenyl]pyridine-2-carboxamidine
AKOS040751409

Bioavailability

ExcerptReference
" Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice."( Novel arylimidamides for treatment of visceral leishmaniasis.
Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X, 2010)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (210)

Assay IDTitleYearJournalArticle
AID533177Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in liver parasitemia at 50 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533487Renal toxicity in BALB/c mouse assessed as blood urea nitrogen level in serum at 30 mg/kg/day, iv administered for five days (Rvb= 20 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533184Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in bone marrow parasitemia at 30 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533190Clearance in Swiss Webster mouse at 1 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564753Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 50 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 8 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533720Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 1 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564739Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y infected in Swiss mouse cardiomyocytes assessed as intracellular parasitemia at 10.6 uM after 72 hrs by Pizzi-Brener method2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533702Half life in human liver microsome by HPLC-MS/MS analysis in presence of 1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564734Antitrypanosomal activity against Trypanosoma cruzi MS1523 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533496Renal toxicity in BALB/c mouse assessed as blood urea nitrogen level in serum at 25 mg/kg/day, po administered for five days (Rvb= 29 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564081Antitrypanosomal activity against Trypanosoma cruzi 958 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564074Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Columbian after 24 hrs by light microscopy in presence of 50% mouse blood2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533711Half life in golden Syrian hamster liver microsome by HPLC-MS/MS analysis in presence of 1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533712Half life in golden Syrian hamster liver microsome by HPLC-MS/MS analysis in presence of 10 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563571Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasitemia at 100 mg/kg/day, ip administered 8 days postinfection measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID563564Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite-induced cardiac inflammation in mouse at 100 mg/kg/day, ip administered 5 days postinfection for 10 alternate days mea2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533736Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 50 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533706Half life in rat liver microsome by HPLC-MS/MS analysis in presence of 10 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID675040Binding affinity to poly(dA-dT)n DNA assessed as increase in melting temperature at 0.3 mol compound per mole of DNA by spectrophotometry2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides.
AID533717Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 100 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533159Antileishmanial activity against antimony resistant Leishmania donovani MC4-R infected in mouse J774 macrophage2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533440AUC (0 to infinity) in Swiss Webster mouse at 5 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533160Antileishmanial activity against antimony resistant Leishmania donovani MC8-R infected in mouse J774 macrophage2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563573Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss-Webster mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 5 days post-infection for 10 consecutive days measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533181Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in spleen parasitemia at 50 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533472Hepatotoxicity in BALB/c mouse assessed as ALT level in serum at 5 mg/kg/day, iv administered for five days (Rvb= 34 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563556Toxicity in CH3/He(H-2k) mouse assessed as effect on creatine kinase level at 100 mg/kg/day, ip2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID563572Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival rate of mouse at 100 mg/kg/day, ip administered 8 days postinfection measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564079Antitrypanosomal activity against Trypanosoma cruzi 875 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533497Renal toxicity in BALB/c mouse assessed as blood urea nitrogen level in serum at 50 mg/kg/day, po administered for five days (Rvb= 29 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533432Volume of distribution in Swiss Webster mouse at 66 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564774Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load in 25 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 120 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564771Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 25 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 120 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533713Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 1 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533441Cmax in Swiss Webster mouse at 5 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533447Tmax in Swiss Webster mouse at 70 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564080Antitrypanosomal activity against Trypanosoma cruzi 956 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533155Antileishmanial activity against intracellular Leishmania amazonensis amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533162Toxicity in BALB/c mouse at 50 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533725Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 500 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564749Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 50 mg/kg/day, ip administered 8 days postinfection measured on day 22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564077Antitrypanosomal activity against Trypanosoma cruzi 762 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533723Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 50 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533185Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in bone marrow parasitemia at 50 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533750Half life in Swiss Webster mouse at 70 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533704Half life in rat liver microsome by HPLC-MS/MS analysis in presence of 0.1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533501Hepatotoxicity in BALB/c mouse assessed as alkaline phosphatase level in serum at 50 mg/kg/day, po administered for five days (Rvb= 129 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID1156608Antiparasitic activity against Trypanosoma brucei rhodesiense STIB900 trypomastigotes after 3 days by Alamar blue assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID533176Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in liver parasitemia at 30 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533186Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in bone marrow parasitemia at 100 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533452Drug level in BALB/c mouse spleen at 5 mg/kg, iv after 2 hrs by HPLC/UV analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533157Antileishmanial activity against intracellular Leishmania donovani LV82 amastigotes infected in CD-1 mouse peritoneal macrophage2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564758Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as reduction in parasite-induced weight loss in mouse at 100 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured 2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533733Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 1 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563563Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in cardiac parasite load at 100 mg/kg/day, ip administered 5 days postinfection for 10 alternate days measured after 14 days posti2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564070Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533468Hepatotoxicity in BALB/c mouse assessed as AST level in serum at 5 mg/kg/day, iv administered for five days (Rvb= 65 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564779Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as survival of mouse at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 31 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533705Half life in rat liver microsome by HPLC-MS/MS analysis in presence of 1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563561Cardiotoxicity in CH3/He(H-2k) mouse assessed as effect on heart rate level at 100 mg/kg/day, ip2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533749Half life in Swiss Webster mouse at 5 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564768Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as reduction in parasite-induced weight loss at 100 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 120 d2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564072Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y after 24 hrs by light microscopy in presence of 50% mouse blood2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533180Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in spleen parasitemia at 30 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533456Drug level in BALB/c mouse kidney at 70 mg/kg, po after 2 hrs by HPLC/UV analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533696Hepatotoxicity in BALB/c mouse assessed as alkaline phosphatase in serum at 150 mg/kg/day, po administered for five days (Rvb= 129 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564754Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival of mouse at 25 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533709Half life in mouse liver microsome by HPLC-MS/MS analysis in presence of 10 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533174Antileishmanial activity against Leishmania donovani promastigotes in BALB/c mouse assessed as inhibition of liver parasitemia at 100 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID612454Antileishmanial activity against beta-lactamase transfected Leishmania amazonensis promastigotes infected in macrophages after 72 hrs by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.
AID533451Drug level in BALB/c mouse liver at 5 mg/kg, iv after 2 hrs by HPLC/UV analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533710Half life in golden Syrian hamster liver microsomes by HPLC-MS/MS analysis in presence of 0.1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564752Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 25 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 8 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533483Hepatotoxicity in BALB/c mouse assessed as ALT level in serum at 100 mg/kg/day, po administered for five days (Rvb= 36 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533734Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 5 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533738Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 500 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533716Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 50 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563558Toxicity in CH3/He(H-2k) mouse assessed as effect on GPT level at 100 mg/kg/day, pi2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564742Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y infected in Swiss mouse cardiomyocytes assessed as parasite crista dilation at 10 ug/ml after 2 hrs by transmission electron microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533491Hepatotoxicity in BALB/c mouse assessed as alkaline phosphatase level in serum at 30 mg/kg/day, iv administered for five days (Rvb= 134 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564741Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y infected in Swiss mouse cardiomyocytes assessed as parasite mitochondrial swelling at 10 ug/ml after 24 hrs by transmission electron microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533471Hepatotoxicity in BALB/c mouse assessed as AST level in serum at 30 mg/kg/day, iv administered for five days (Rvb= 65 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533173Antileishmanial activity against Leishmania donovani promastigotes in po dosed BALB/c mouse assessed as inhibition of liver parasitemia2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533480Hepatotoxicity in BALB/c mouse assessed as ALT level in serum at 25 mg/kg/day, po administered for five days (Rvb= 36 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564733Antitrypanosomal activity against Trypanosoma cruzi 960 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533449Volume of distribution in Swiss Webster mouse at 70 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564750Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival of mouse at 25 mg/kg/day, ip administered 8 days postinfection measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564772Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 50 mg/kg/day, ip p administered 5 days postinfection for 10 consecutive days measured after 120 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533182Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in spleen parasitemia at 100 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533494Renal toxicity in BALB/c mouse assessed as phosphorus level in serum at 20 mg/kg/day, iv administered for five days (Rvb= 6.1 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564773Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 41days post infection2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533187AUC (0 to infinity) in Swiss Webster mouse at 1 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID675037Antileishmanial activity against intracellular Leishmania amazonensis2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides.
AID533450Oral bioavailability in Swiss Webster mouse at 70 mg/kg by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563569Toxicity in CH3/He(H-2k) mouse assessed as mortality at cumulative dose of 100 mg/kg, ip measured after 48 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533730Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 50 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533158Antileishmanial activity against antimony resistant Leishmania donovani AG83-S infected in mouse J774 macrophage2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564071Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y after 24 hrs by light microscopy in presence of 96% mouse blood2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID563566Hepatotoxicity against Swiss-Webster mouse assessed as GPT at 100 mg/kg/day measured after 14 days postinfection2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1156607Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Leishmania amazonensis2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID533715Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 10 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564746Toxicity in male Swiss-Webster mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533445AUC (0 to infinity) in Swiss Webster mouse at 70 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533727Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 1 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563575Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as increase in survival rate at 25 mg/kg/day, ip administered 120 days postinfection measured on day 22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533728Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 5 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533708Half life in mouse liver microsome by HPLC-MS/MS analysis in presence of 1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533490Hepatotoxicity in BALB/c mouse assessed as alkaline phosphatase level in serum at 20 mg/kg/day, iv administered for five days (Rvb= 134 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533732Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 500 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563568Selectivity ratio of IC50 for Trypanosoma cruzi Y bloodstream forms to IC50 for Trypanosoma cruzi Y amastigotes2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533698Renal toxicity in BALB/c mouse assessed as phosphorus level in serum at 50 mg/kg/day, po administered for five days (Rvb= 5.3 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563559Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss-Webster mouse assessed as decrease in parasite-induced weight loss at 100 mg/kg/day, ip administered 5 days post-infection for 10 consecutive days measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID563565Cytotoxicity against Swiss-Webster mouse assessed as effect on creatine kinase at 100 mg/kg/day measured after 14 days postinfection2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533455Drug level in BALB/c mouse spleen at 70 mg/kg, po after 2 hrs by HPLC/UV analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533700Renal toxicity in BALB/c mouse assessed as phosphorus in serum at 150 mg/kg/day, po administered for five days (Rvb= 5.3 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533499Renal toxicity in BALB/c mouse assessed as blood urea nitrogen level in serum at 150 mg/kg/day, po administered for five days (Rvb= 29 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533179Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in spleen parasitemia at 10 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID675039Cytotoxicity against rat L6 cells2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides.
AID1156611Selectivity index, ratio of IC50 for rat L6 cells to IC50 for chloroquine-resistant Plasmodium falciparum K12014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID533446Cmax in Swiss Webster mouse at 70 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID612453Antileishmanial activity against Leishmania donovani axenic amastigotes after 3 days by tetrazolium dye based spectrophotometric analysis at pH 5.52011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.
AID533183Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in bone marrow parasitemia at 10 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533724Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 100 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564776Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 50 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 41 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533474Hepatotoxicity in BALB/c mouse assessed as ALT level in serum at 20 mg/kg/day, iv administered for five days (Rvb= 34 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533707Half life in mouse liver microsome by HPLC-MS/MS analysis in presence of 0.1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533444Volume of distribution in Swiss Webster mouse at 5 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533443Clearance in Swiss Webster mouse at 5 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564736Cytotoxicity against Swiss-Webster mouse cardiomyocytes after 24 hrs by MTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564748Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as decrease in parasite load at 25 mg/kg/day, ip administered 8 days postinfection measured on day 22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533453Drug level in BALB/c mouse kidney at 5 mg/kg, iv after 2 hrs by HPLC/UV analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564737Cytotoxicity against Swiss-Webster mouse cardiomyocytes after 72 hrs by MTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533744Half life in Swiss Webster mouse at 1 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533454Drug level in BALB/c mouse liver at 70 mg/kg, po after 2 hrs by HPLC/UV analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID675038Antileishmanial activity against intracellular Leishmania donovani2012European journal of medicinal chemistry, Sep, Volume: 55Synthesis, DNA binding and antileishmanial activity of low molecular weight bis-arylimidamides.
AID533154Antileishmanial activity against intracellular Leishmania donovani LV82 amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564781Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite-induced cardiac inflammation at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured aft2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID563557Toxicity in CH3/He(H-2k) mouse assessed as effect on GPT level at 100 mg/kg/day, po2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564069Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y after 2 hrs by light microscopy in presence of 96% mouse blood2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533163Toxicity in BALB/c mouse assessed as hypoactivity at 50 mg/kg/day, ip administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564078Antitrypanosomal activity against Trypanosoma cruzi 855 epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533188Cmax in Swiss Webster mouse at 1 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564068Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms after 2 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID563567Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as reduction in parasite-induced weight loss at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564744Toxicity in CH3/He(H-2k) mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1156604Antiparasitic activity against Trypanosoma cruzi Tulahen LacZ/C4 amastigotes after 4 days by beta-galactosidase reporter gene assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID1156606Antiparasitic activity against Leishmania amazonensis infected in CD-1 mouse macrophages after 72 hrs by spectrophotometric analysis2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID564073Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi YuYu after 24 hrs by light microscopy in presence of 50% mouse blood2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564760Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as reduction in parasite-induced weight loss in mouse at 50 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured o2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1156603Cytotoxicity against rat L6 cells after 3 days by Alamar blue assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID533703Half life in human liver microsome by HPLC-MS/MS analysis in presence of 10 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564770Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as reduction in parasite-induced weight loss at 50 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 120 da2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533729Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 10 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533448Clearance in Swiss Webster mouse at 70 mg/kg, po by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533488Hepatotoxicity in BALB/c mouse assessed as alkaline phosphatase level in serum at 5 mg/kg/day, iv administered for five days (Rvb= 134 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533459Toxicity in BALB/c mouse at 100 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533458Toxicity in BALB/c mouse assessed as occurrence of tremor at 50 mg/kg, iv2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564743Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss mouse cardiomyocytes assessed as parasite crista dilation at 10 ug/ml after 24 hrs by transmission electron microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564778Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 31 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533714Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 5 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564763Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 50 mg/kg/day, ip administered 21 days postinfection measured on day 452010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564076Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533492Renal toxicity in BALB/c mouse assessed as phosphorus level in serum at 5 mg/kg/day, iv administered for five days (Rvb= 6.1 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID563574Antitrypanosomal activity against Trypanosoma cruzi Y infected in Swiss-Webster mouse assessed as decrease in parasite-induced weight loss at 100 mg/kg/day, po administered 5 days post-infection for 10 consecutive days measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533737Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 100 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564075Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi CL after 24 hrs by light microscopy in presence of 50% mouse blood2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533701Half life in human liver microsome by HPLC-MS/MS analysis in presence of 0.1 uM NADPH2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533486Renal toxicity in BALB/c mouse assessed as blood urea nitrogen level in serum at 20 mg/kg/day, iv administered for five days (Rvb= 20 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564755Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival of mouse at 50 mg/kg/day, ip p administered 5 days postinfection for 10 consecutive days measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564777Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as survival of mouse at 100 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 31 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564745Toxicity in female Swiss-Webster mouse assessed as mortality at cumulative dose of 200 mg/kg, ip measured after 48 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564751Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as survival of mouse at 50 mg/kg/day, ip administered 8 days postinfection measured on day 1202010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533722Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 10 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533175Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in liver parasitemia at 10 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533477Hepatotoxicity in BALB/c mouse assessed as AST level in serum at 50 mg/kg/day, po administered for five days (Rvb= 70 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564761Antitrypanosomal activity against Trypanosoma cruzi Y amastigotes infected in Swiss-Webster CM cells assessed as parasite DNA to host cell nucleus ratio at 10 ug/ml after 1 hr by fluorescence and transmission electron microscopy analysis2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564735Antitrypanosomal activity against Trypanosoma cruzi RBVIII epimastigotes after 24 hrs by light microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533470Hepatotoxicity in BALB/c mouse assessed as AST level in serum at 20 mg/kg/day, iv administered for five days (Rvb= 65 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID1156609Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei rhodesiense STIB900 trypomastigotes2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID564780Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in cardiac parasite load at 100 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 43 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533481Hepatotoxicity in BALB/c mouse assessed as ALT level in serum at 50 mg/kg/day, po administered for five days (Rvb= 36 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533156Antileishmanial activity against intracellular Leishmania major amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564747Toxicity in male Swiss-Webster mouse assessed as weight loss at cumulative dose of 200 mg/kg, ip measured after 48 hrs2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564740Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y infected in Swiss mouse cardiomyocytes assessed as parasite mitochondrial swelling at 10 ug/ml after 2 hrs by transmission electron microscopy2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533171Antileishmanial activity against Leishmania donovani promastigotes in BALB/c mouse assessed as inhibition of liver parasitemia at 30 mg/kg/day, ip administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533153Antileishmanial activity against Leishmania donovani axenic amastigotes2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID1156605Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma cruzi Tulahen LacZ/C4 amastigotes2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID563576Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as increase in survival rate at 50 mg/kg/day, ip administered 120 days postinfection measured on day 22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID1156610Antiparasitic activity against chloroquine-resistant Plasmodium falciparum K1 after 3 days by [3H]-hypoxanthine incorporation assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID533484Renal toxicity in BALB/c mouse assessed as blood urea nitrogen level in serum at 5 mg/kg/day, iv administered for five days (Rvb= 20 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533442Tmax in Swiss Webster mouse at 5 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533697Hepatotoxicity in BALB/c mouse assessed as phosphorus level in serum at 25 mg/kg/day, po administered for five days (Rvb= 5.3 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533462Toxicity in BALB/c mouse assessed as occurrence of tremor at 20 mg/kg/day, iv administered for five days measured on day 22010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533500Hepatotoxicity in BALB/c mouse assessed as alkaline phosphatase level in serum at 25 mg/kg/day, po administered for five days (Rvb= 129 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533170Antileishmanial activity against Leishmania donovani promastigotes in ip dosed BALB/c mouse assessed as inhibition of liver parasitemia2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533735Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 10 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533476Hepatotoxicity in BALB/c mouse assessed as AST level in serum at 25 mg/kg/day, po administered for five days (Rvb= 70 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533721Induction of mutagenicity in Salmonella serovar Typhimurium TA 100 assessed as number of revertant colonies at 5 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564775Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load in 50 mg/kg/day, po administered 5 days postinfection for 10 consecutive days measured after 120 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533718Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 500 ug by Ames assay in presence of Aroclor 1254-induced rat liver S9 metabolic activation system2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533475Hepatotoxicity in BALB/c mouse assessed as ALT level in serum at 30 mg/kg/day, iv administered for five days (Rvb= 34 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564762Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as decrease in parasite load at 25 mg/kg/day, ip administered 21 days postinfection measured on day 442010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533178Antileishmanial activity against Leishmania donovani WR378 infected in golden Syrian hamster assessed as reduction in liver parasitemia at 100 mg/kg/day, po administered for five days2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533731Induction of mutagenicity in Salmonella serovar Typhimurium TA 98 assessed as number of revertant colonies at 100 ug by Ames assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID533479Hepatotoxicity in BALB/c mouse assessed as AST level in serum at 100 mg/kg/day, po administered for five days (Rvb= 70 U/L)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564769Antitrypanosomal activity against Trypanosoma cruzi Columbian bloodstream forms infected in C3H mouse assessed as reduction in parasite-induced weight loss at 25 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured after 120 da2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533495Renal toxicity in BALB/c mouse assessed as phosphorus level in serum at 30 mg/kg/day, iv administered for five days (Rvb= 6.1 mg/dl)2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
AID564738Cardiotoxicity against Swiss-Webster mouse cardiomyocytes assessed as creatine kinase cardiac isotype level by MTT assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID564759Antitrypanosomal activity against Trypanosoma cruzi Y bloodstream forms infected in Swiss-Webster mouse assessed as reduction in parasite-induced weight loss in mouse at 25 mg/kg/day, ip administered 5 days postinfection for 10 consecutive days measured o2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.
AID533191Volume of distribution in Swiss Webster mouse at 1 mg/kg, iv by HPLC-MS/MS analysis2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Novel arylimidamides for treatment of visceral leishmaniasis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.110aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
miltefosine
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.		2.0510phosphocholines;
phospholipid		anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		2.4820aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
melarsoprol
Melarsoprol: Arsenical used in trypanosomiases. It may cause fatal encephalopathy and other undesirable side effects.		2.110triazines
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.110furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
2-nitrofluorene
2-nitrofluorene: RN given refers to cpd with locant with nitro moiety in 2 position. 2-nitrofluorene : A nitroarene that is fluorene substituted by a nitro group at position 2.		2.0510nitroarenecarcinogenic agent;
mutagen
2-anthramine
2-anthramine: structure		2.0510anthracenamine
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		2.4820C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
sodium azide
Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).		2.0510inorganic sodium saltantibacterial agent;
explosive;
mitochondrial respiratory-chain inhibitor;
mutagen
furamidine
furamidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this		2.0510
paromomycin
Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.		2.0510amino cyclitol glycoside;
aminoglycoside antibiotic		anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.4820antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Parasitemia
The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)		02.0510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Black Fever
[description not available]		02.0510
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.0510
American Trypanosomiasis
[description not available]		02.0510
Chagas Disease
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.		02.0510
Leishmania Infection
[description not available]		02.0610
Leishmaniasis
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).		02.0610